RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $41

Benzinga · 23h ago
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $38 to $41.